Trademark: 79248825
Word

Status
Registered
Status Code
700
Status Date
Tuesday, November 12, 2019
Serial Number
79248825
Registration Number
5905800
Registration Date
Tuesday, November 12, 2019
Mark Type
2000
Filing Date
Friday, August 10, 2018
Published for Opposition
Tuesday, August 27, 2019

Trademark Owner History
Jiangsu Ascentage Pharma Inc. - Original Registrant
JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC. - Owner At Publication

Classifications
5 Medicines for human purposes, namely, medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; bacterial poisons; pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; chemico-pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; drugs for medical purposes in the nature of prescription apoptosis targeted compounds, next-generation kinase inhibitors and senolytic drugs; prescription drugs for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biological preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; medicines for dental purposes; chemical preparations for pharmaceutical or medical purposes, namely, for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antibiotics; pharmaceutical preparations in the form of injectionable pharmaceutical preparations for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; pharmaceutical preparations in the form of tablet for the treatment of cancer, tumors, blood-related diseases, infectious diseases, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; active pharmaceutical ingredients in the nature of drug delivery agents in the form of powders, liquids, and capsules that provide controlled release of active ingredients for a wide variety of pharmaceuticals; active pharmaceutical ingredients in the nature of drug delivery agents in the form of tablets, lozenges, chews, gels, fast dispersing dosage forms, films, ovules, sprays, buccal/mucoadhesive patches for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; biochemical medicines for the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; antiseptics; collyrium; suppositories; medicinal oils; transdermal patches for use in the treatment of cancer, tumors, blood-related diseases, infectious diseases, osteoarthritis, age-related diseases, fibrotic diseases, Crohn's disease, and cardiovascular disease; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; candy, medicated; candy for medical purposes; dietetic foods adapted for medical purposes; dietetic beverages adapted for medical purposes; dietetic substances in the nature of foods and beverages adapted for medical use; mineral food supplements; nutritional supplements
The mark consists of a design image forming an open semi-circle comprised of two lines displayed in a semi-circular manner, one of which extends at the end to form a zig-zag pattern and an additional zig-zag shaped line displayed next to such zig-zag extension.
Color is not claimed as a feature of the mark.

Trademark Events
Apr 1, 2024
Teas Withdrawal Of Attorney Received-Firm Retains
Apr 1, 2024
Teas Change Of Correspondence Received
Apr 1, 2024
Attorney/Dom.Rep.Revoked And/Or Appointed
Apr 1, 2024
Teas Revoke/App/Change Addr Of Atty/Dom Rep Received
Apr 1, 2024
Applicant/Correspondence Changes (Non-Responsive) Entered
Apr 1, 2024
Teas Change Of Owner Address Received
Mar 27, 2023
Change Of Name/Address Rec'd From Ib
Dec 25, 2022
New Representative At Ib Received
May 8, 2020
Final Decision Transaction Processed By Ib
Mar 7, 2020
Generic Madrid Transaction Sent To Ib
Mar 6, 2020
Generic Madrid Transaction Created
Feb 12, 2020
Final Disposition Notice Created, To Be Sent To Ib
Nov 12, 2019
Registered-Principal Register
Aug 27, 2019
Official Gazette Publication Confirmation E-Mailed
Aug 27, 2019
Published For Opposition
Aug 23, 2019
Notification Processed By Ib
Aug 7, 2019
Notification Of Possible Opposition Sent To Ib
Aug 7, 2019
Notice Of Start Of Opposition Period Created, To Be Sent To Ib
Aug 7, 2019
Notification Of Notice Of Publication E-Mailed
Jul 22, 2019
Assigned To Lie
Jul 16, 2019
Approved For Pub - Principal Register
Jul 16, 2019
Examiner's Amendment Entered
Jul 16, 2019
Notification Of Examiners Amendment E-Mailed
Jul 16, 2019
Examiners Amendment E-Mailed
Jul 16, 2019
Examiners Amendment -Written
Jun 14, 2019
Teas/Email Correspondence Entered
Jun 13, 2019
Correspondence Received In Law Office
Jun 13, 2019
Teas Response To Office Action Received
Feb 16, 2019
Refusal Processed By Ib
Jan 26, 2019
Non-Final Action Mailed - Refusal Sent To Ib
Jan 26, 2019
Refusal Processed By Mpu
Jan 16, 2019
Non-Final Action (Ib Refusal) Prepared For Review
Jan 15, 2019
Non-Final Action Written
Jan 15, 2019
Application Filing Receipt Mailed
Jan 11, 2019
Assigned To Examiner
Jan 11, 2019
New Application Office Supplied Data Entered
Jan 3, 2019
Sn Assigned For Sect 66a Appl From Ib

Trademark Alertz updated from USPTO on 2030-01-24